Fortis Malar [FORTISMLR] vs Indraprastha Medical [INDRAMEDCO] Detailed Stock Comparison

Fortis Malar
BSE
Loading...

Indraprastha Medical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Fortis Malar wins in 7 metrics, Indraprastha Medical wins in 12 metrics, with 0 ties. Indraprastha Medical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Fortis Malar | Indraprastha Medical | Better |
---|---|---|---|
P/E Ratio (TTM) | 27.91 | 24.93 | Indraprastha Medical |
Price-to-Book Ratio | 4.26 | 7.02 | Fortis Malar |
Debt-to-Equity Ratio | 0.00 | 5.49 | Fortis Malar |
PEG Ratio | 0.00 | 1.67 | Fortis Malar |
EV/EBITDA | 166.65 | 15.39 | Indraprastha Medical |
Profit Margin (TTM) | 22,483.90% | 12.21% | Fortis Malar |
Operating Margin (TTM) | -1,572.20% | 17.25% | Indraprastha Medical |
EBITDA Margin (TTM) | N/A | 17.25% | N/A |
Return on Equity | 1.30% | 26.98% | Indraprastha Medical |
Return on Assets (TTM) | 1.06% | 18.90% | Indraprastha Medical |
Free Cash Flow (TTM) | $15.44M | $1.20B | Indraprastha Medical |
Dividend Yield | 3.38% | 1.13% | Fortis Malar |
1-Year Return | 11.89% | 17.58% | Indraprastha Medical |
Price-to-Sales Ratio (TTM) | 6,278.05 | 3.05 | Indraprastha Medical |
Enterprise Value | $964.75M | $38.97B | Indraprastha Medical |
EV/Revenue Ratio | 4,706.12 | 2.84 | Indraprastha Medical |
Gross Profit Margin (TTM) | 100.00% | 38.19% | Fortis Malar |
Revenue per Share (TTM) | $0 | $150 | Indraprastha Medical |
Earnings per Share (Diluted) | $2.46 | $18.30 | Indraprastha Medical |
Beta (Stock Volatility) | -0.08 | 0.59 | Fortis Malar |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Fortis Malar vs Indraprastha Medical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Fortis Malar | -0.36% | 0.23% | -3.60% | -8.27% | 17.31% | 11.57% |
Indraprastha Medical | -0.36% | 0.16% | -1.70% | 8.50% | 16.31% | -13.52% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Fortis Malar | 11.89% | 18.57% | 40.49% | 54.71% | 104.98% | 296.37% |
Indraprastha Medical | 17.58% | 574.59% | 788.15% | 664.90% | 906.44% | 914.07% |
Performance & Financial Health Analysis: Fortis Malar vs Indraprastha Medical
Metric | FORTISMLR | INDRAMEDCO |
---|---|---|
Market Information | ||
Market Cap | ₹1.29B | ₹41.83B |
Market Cap Category | Small cap | Small cap |
10 Day Avg. Volume | 14,440 | 273,122 |
90 Day Avg. Volume | 14,545 | 220,572 |
Last Close | ₹68.52 | ₹466.80 |
52 Week Range | ₹51.01 - ₹98.70 | ₹307.25 - ₹572.00 |
% from 52W High | -30.58% | -18.39% |
All-Time High | ₹107.94 (Apr 22, 2024) | ₹572.00 (Jan 06, 2025) |
% from All-Time High | -36.52% | -18.39% |
Growth Metrics | ||
Quarterly Revenue Growth | N/A | 0.05% |
Quarterly Earnings Growth | N/A | 0.15% |
Financial Health | ||
Profit Margin (TTM) | 224.84% | 0.12% |
Operating Margin (TTM) | -15.72% | 0.17% |
Return on Equity (TTM) | 0.01% | 0.27% |
Debt to Equity (MRQ) | 0.00 | 5.49 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹16.12 | ₹65.04 |
Cash per Share (MRQ) | ₹17.19 | ₹35.08 |
Operating Cash Flow (TTM) | ₹-10,605,000 | ₹1.78B |
Levered Free Cash Flow (TTM) | ₹3.92M | ₹1.61B |
Dividends | ||
Last 12-Month Dividend Yield | 3.38% | 1.13% |
Last 12-Month Dividend | ₹2.50 | ₹4.50 |
Valuation & Enterprise Metrics Analysis: Fortis Malar vs Indraprastha Medical
Metric | FORTISMLR | INDRAMEDCO |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | 27.91 | 24.93 |
Forward P/E | N/A | 182.52 |
PEG Ratio | 0.00 | 1.67 |
Price to Sales (TTM) | 6,278.05 | 3.05 |
Price to Book (MRQ) | 4.26 | 7.02 |
Market Capitalization | ||
Market Capitalization | ₹1.29B | ₹41.83B |
Enterprise Value | ₹964.75M | ₹38.97B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 4,706.12 | 2.84 |
Enterprise to EBITDA | 166.65 | 15.39 |
Risk & Other Metrics | ||
Beta | -0.08 | 0.59 |
Book Value per Share (MRQ) | ₹16.12 | ₹65.04 |
Financial Statements Comparison: Fortis Malar vs Indraprastha Medical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | FORTISMLR | INDRAMEDCO |
---|---|---|
Revenue/Sales | ₹205,000 | ₹3.34B |
Cost of Goods Sold | ₹0 | ₹2.13B |
Gross Profit | ₹205,000 | ₹1.21B |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹42.85M | ₹504.10M |
EBITDA | ₹42.85M | ₹676.70M |
Pre-Tax Income | ₹42.85M | ₹552.70M |
Income Tax | ₹1.32M | ₹142.60M |
Net Income (Profit) | ₹41.53M | ₹410.10M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | FORTISMLR | INDRAMEDCO |
---|---|---|
Cash & Equivalents | ₹2.02M | ₹614.80M |
Total Current Assets | ₹341.12M | ₹4.31B |
Total Current Liabilities | ₹66.23M | ₹1.79B |
Long-Term Debt | N/A | ₹305.40M |
Total Shareholders Equity | ₹302.09M | ₹5.97B |
Retained Earnings | ₹18.80M | N/A |
Property, Plant & Equipment | ₹0 | ₹3.27B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | FORTISMLR | INDRAMEDCO |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | FORTISMLR | INDRAMEDCO |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 14,440 | 273,122 |
Average Daily Volume (90 Day) | 14,545 | 220,572 |
Shares Outstanding | 18.74M | 91.67M |
Float Shares | 4.82M | 41.01M |
% Held by Insiders | 0.72% | 0.58% |
% Held by Institutions | 0.00% | 0.03% |
Dividend Analysis & Yield Comparison: Fortis Malar vs Indraprastha Medical
Metric | FORTISMLR | INDRAMEDCO |
---|---|---|
Last 12-Month Dividend | ₹2.50 | ₹4.50 |
Last 12-Month Dividend Yield | 3.38% | 1.13% |
3-Year Avg Annual Dividend | ₹14.17 | ₹3.33 |
3-Year Avg Dividend Yield | 26.20% | 2.17% |
3-Year Total Dividends | ₹42.50 | ₹10.00 |
Ex-Dividend Date | Jul 24, 2024 | Sep 13, 2024 |